Charcot’s foot is a progressive condition in which severe nerve damage causes the bones of the foot to weaken, fracture, and eventually collapse, reshaping the foot into a deformity that can look like the sole of a rocking chair. It most commonly affects people with diabetes who have lost sensation in their feet, though it can follow any condition that causes significant peripheral neuropathy. Because the foot is numb, a person can walk on breaking bones for weeks without realizing anything is wrong, which is what makes the condition so destructive and so easy to miss.
How the Foot Breaks Down
The basic problem is a mismatch between ongoing physical stress and the body’s ability to feel and respond to it. When you lose sensation in your feet, you also lose the protective reflexes that cause you to shift your weight away from a sore spot or limp when something hurts. Minor injuries, small stress fractures, or even the routine impact of walking can go completely unnoticed. Two longstanding theories explain what happens next, and modern research suggests both are partly right. One idea, sometimes called the neuro-traumatic theory, holds that repeated undetected trauma accumulates until bones fracture and joints dislocate. The other, the neurovascular theory, proposes that nerve damage increases blood flow to the bones in the foot, gradually weakening them and making them more vulnerable to fracture.
What ties these ideas together is inflammation. Researchers have proposed that an initial insult to the foot, which may be so minor the person never notices it, triggers an inflammatory cascade involving molecules like TNF-alpha and interleukin-1 beta. This inflammation ramps up the activity of osteoclasts, the cells responsible for breaking down bone tissue. In a healthy foot, bone breakdown is balanced by bone rebuilding. In a Charcot foot, the balance tips sharply toward destruction.1The Lancet. The pathogenesis of acute Charcot neuroarthropathy: a unifying hypothesis A key molecular pathway involves a signaling system called RANKL-RANK-OPG. In the acute phase of Charcot’s foot, there is an overexpression of RANKL, which drives osteoclast activity into overdrive, dissolving bone in a process that sets the stage for fractures and architectural collapse.2PubMed Central. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications
Each fracture that goes unnoticed fuels more inflammation, which drives more bone loss, which causes more fractures. It is a self-reinforcing loop. Without intervention, the arch of the foot can completely collapse, leaving the person walking on a rounded mass of dislocated bones and soft tissue.
Who Is at Risk
Diabetes is by far the most common underlying cause today. People with longstanding diabetes who have peripheral neuropathy, meaning they have significantly reduced or absent feeling in their feet, are the primary group affected. The condition was originally described in the context of neurosyphilis. Jean-Martin Charcot first identified the joint destruction associated with tabes dorsalis in the late 1800s, and the link between this type of bone damage and diabetes was not established until 1936.3PubMed. The Charcot foot: historical perspective 1827-2003 With syphilis now treatable with antibiotics, diabetes accounts for the vast majority of cases. That said, any condition that destroys peripheral nerves can theoretically set the stage, including chronic alcoholism, spinal cord injuries, and certain autoimmune neuropathies.4PubMed Central. Charcot osteoarthropathy of the knee secondary to neurosyphilis: a rare condition managed by a challenging arthrodesis
Not everyone with diabetic neuropathy develops a Charcot foot, and researchers still do not fully understand why some people’s bones collapse while others with equally numb feet never have the problem. Factors that seem to increase risk include a longer duration of diabetes, poor blood sugar control, obesity, and kidney disease. The midfoot is the most commonly affected area, though the ankle, hindfoot, and even the knee can be involved in rarer cases.
Why It Is So Often Misdiagnosed
The earliest sign of an acute Charcot foot is usually a red, hot, swollen foot in someone who has diabetes. The problem is that the same description fits a skin infection (cellulitis), a deep-tissue infection, gout, a deep vein thrombosis, or osteomyelitis (bone infection). Many patients are initially treated with antibiotics for a presumed infection, and the Charcot diagnosis only comes weeks or months later when the foot has already started to deform.
Early X-rays can look normal. The earliest phase of the condition, sometimes called Stage 0, is radiographically silent, meaning standard X-rays show nothing unusual even though the destructive process has already begun. MRI can detect bone marrow swelling and early ligament changes at this stage, which is why it is the preferred imaging tool when Charcot’s foot is suspected but X-rays are unremarkable.5Indian Journal of Musculoskeletal Radiology. Imaging challenges in Charcot’s neuroarthropathy and diabetic foot: Distinguishing infective and non-infective conditions
Even with MRI, distinguishing Charcot’s foot from osteomyelitis can be genuinely difficult. Both conditions cause bone marrow edema and soft-tissue swelling, and both occur in the same patient population. Certain MRI features, like the pattern and distribution of the swelling, can help separate the two, but there are scenarios where the findings overlap or, worse, where both conditions are present at the same time.6PubMed. Advanced MR Imaging Techniques for Differentiation of Neuropathic Arthropathy and Osteomyelitis in the Diabetic Foot Advanced imaging techniques, including diffusion-weighted MRI and PET/CT scanning, have shown promise in making the distinction more reliable. In one study comparing these approaches, visual assessment on PET/CT had the highest diagnostic accuracy for telling the two apart.7PubMed. Comparison of the diagnostic accuracy of diffusion-weighted and dynamic contrast-enhanced MRI with (18)F-FDG PET/CT to differentiate osteomyelitis from Charcot neuro-osteoarthropathy in diabetic foot
A practical bedside tool that has proven useful is skin temperature monitoring. An actively inflamed Charcot foot is measurably warmer than the opposite foot. Comparing the temperature of both feet with an infrared thermometer is a simple, non-invasive way to flag the condition early and to track whether treatment is working. Research has shown that the temperature difference decreases in a predictable pattern as the acute phase resolves.8PubMed Central. Infrared Dermal Thermometry in Active Charcot Neuro-Osteoarthropathy of Foot 9Journal of Rehabilitation Research and Development. Monitoring healing of acute Charcot’s arthropathy with infrared dermal thermometry
Stages of the Disease
Clinicians typically describe Charcot’s foot using a three-stage classification system. In Stage 1, the acute or developmental phase, the foot is hot, swollen, and red. X-rays may show fragmentation of bone, joint dislocations, and weakened bone around the joints. This is the most dangerous phase because the architecture of the foot is actively falling apart. In Stage 2, the subacute or coalescent phase, the body starts cleaning up debris: smaller bone fragments are absorbed, larger ones begin to fuse, and early signs of new bone formation appear. Swelling begins to decrease. In Stage 3, the chronic or remodeling phase, the inflammatory process has largely burned out. The bones are healing and hardening, swelling is minimal, and the foot stabilizes, though typically in a deformed shape.10PubMed Central. Classifications in brief: Eichenholtz classification of Charcot arthropathy
The goal of treatment is to protect the foot during Stage 1 so that it reaches Stage 3 with as little deformity as possible. How much deformity remains depends heavily on how early the condition was caught and how aggressively the foot was offloaded.
Treatment With Casting
The cornerstone of treatment for acute Charcot’s foot is total contact casting, often abbreviated TCC. This involves wrapping the foot and lower leg in a rigid cast that distributes weight evenly across the entire sole, preventing any single spot from bearing excessive pressure. The cast also immobilizes the foot, limiting the mechanical forces that drive the cycle of fracture and inflammation. This is not a short commitment. In a retrospective study, the median duration of total contact casting was about four and a half months, though some patients required casting for closer to eight months.11Journal of Foot and Ankle Research. Duration of total contact casting for resolution of acute Charcot foot: a retrospective cohort study
Casting is not without its own problems. Skin irritation is common, and some patients develop pain in other parts of their body from the altered way they walk in a cast. Still, it remains the most cost-effective first-line treatment. A cost analysis of various management approaches found that casting cost roughly $8,200 per patient. When casting failed and patients needed escalation to surgery, the costs jumped dramatically: around $58,000 for a bone-shaving procedure, close to $150,000 for joint fusion surgery, and about $40,000 for a major amputation.12PubMed. Cost-Effective Modeling for Management Options in Charcot Neuroarthropathy The financial case for catching the disease early and managing it conservatively is stark.
There has been interest in whether medications that slow bone breakdown, particularly bisphosphonates like pamidronate, can help during the acute phase. The evidence so far suggests that pamidronate can reduce some markers of disease activity, such as elevated skin temperature and bone turnover markers, but the overall quality of evidence remains low.13PubMed Central. Role of bisphosphonates in the management of acute Charcot foot Bisphosphonates are not standard care but are sometimes used alongside casting in specialist centers.
When Surgery Becomes Necessary
Surgery enters the picture when the foot has deformed to the point that it cannot be safely managed with casting and custom footwear alone, or when instability makes the foot unfunctional or at high risk for ulceration. The two main surgical approaches depend on the problem being addressed.
For feet that have developed a prominent bony bump on the sole, which creates a pressure point and invites ulcers, surgeons can perform an exostectomy, which is essentially shaving down the protruding bone to create a more shoe-friendly shape. This is a less invasive procedure and is suited for patients whose foot is otherwise stable.
For feet with severe instability or collapse, the more definitive option is arthrodesis, or surgical fusion of the affected joints. This involves using hardware like screws, plates, or external frames to lock the bones in a corrected position while they grow together. In cases involving the ankle, both internal fixation (intramedullary nailing) and external frames (Ilizarov fixators) have been used. A comparative study found that both methods achieved good fusion rates, though the external fixator group had a somewhat higher union rate alongside a significantly higher complication rate.14PubMed. Ilizarov External Fixator Versus Retrograde Intramedullary Nailing for Ankle Joint Arthrodesis in Diabetic Charcot Neuroarthropathy Surgery in this population is inherently risky. Wound healing is compromised by diabetes and poor circulation, and infection rates are higher than in the general surgical population.
Life After Charcot’s Foot
Even when the acute process resolves, the foot typically carries some degree of permanent deformity. This is where lifelong footwear management begins. Custom-made therapeutic shoes with molded insoles are designed to redistribute pressure away from vulnerable areas. Research comparing different therapeutic shoe designs for people with chronic Charcot foot deformity found that several types, including rocker-bottom shoes and prefabricated therapeutic shoes, all reduced pressure on the midfoot and hindfoot, though no single design was clearly superior to the others.15PubMed Central. Comparative Analysis of Three Types of Therapeutic Offloading Diabetic Shoes With Custom Made Insole on Plantar Pressure Distribution in Severe Diabetic Charcot Foot The key takeaway is that properly fitted therapeutic footwear is essential, not optional, for anyone who has had a Charcot episode.
Ulcers are the main long-term threat. The deformed foot creates abnormal pressure points, and without sensation to warn of tissue damage, ulcers can develop and worsen quickly. In one cohort analysis, foot ulcers recurred in about 40% of people with Charcot foot deformity. Midfoot ulcers were especially problematic in the Charcot group compared to people with diabetes who had ulcers but no Charcot deformity.16PubMed Central. Foot ulcer recurrence, plantar pressure and footwear adherence in people with diabetes and Charcot midfoot deformity: A cohort analysis Ulcers that become infected can lead to osteomyelitis or, in the worst case, amputation.
The broader impact on quality of life is substantial. People with Charcot’s foot score lower than the general population on measures of physical functioning, social functioning, and general health perception.17PubMed. Long-term outcome and quality of life in patients with Charcot foot A qualitative study exploring patients’ lived experiences found that the physical, social, and emotional burden of the condition is sustained and extends to family members as well. Months of immobilization, repeated clinic visits, the inability to work or drive, and the anxiety of possible amputation all take a toll that clinical metrics do not fully capture.18PubMed Central. A qualitative study to understand people’s experiences of living with Charcot neuroarthropathy
Mortality and the Bigger Health Picture
One finding that surprises many patients and even some clinicians is how strongly Charcot’s foot correlates with reduced life expectancy. A study from a U.K. specialist unit found that life expectancy was reduced by about 14 years in patients presenting with acute Charcot foot compared to the general population.19PubMed Central. Mortality associated with acute Charcot foot and neuropathic foot ulceration This does not mean the Charcot foot itself is directly killing people. Rather, the kind of diabetes severe enough to destroy nerves in the feet is also severe enough to damage the heart, kidneys, and blood vessels. Charcot’s foot is, in many ways, a marker of advanced systemic disease. The people who develop it tend to have more comorbidities, and those comorbidities drive higher healthcare costs, longer hospital stays, and greater mortality.20PubMed. The impact of comorbidities on inpatient Charcot neuroarthropathy cost and utilization
This is why management of Charcot’s foot cannot be just about the foot. Aggressive control of blood sugar, blood pressure, cholesterol, and kidney function all matter. A person diagnosed with Charcot’s foot should be treated as someone with high cardiovascular risk, because statistically, they are.
Emerging Treatments
Researchers continue to look for better ways to speed healing and reduce complications. One newer approach that has shown early promise is pulsed electromagnetic field (PEMF) therapy. In a randomized controlled trial, PEMF therapy applied as an add-on to standard wound care was found to improve both wound healing and bone regeneration in patients with Charcot foot ulcers.21PubMed. Pulsed electromagnetic field stimulation therapy for Charcot foot ulcer: a randomized controlled trial This is still early-stage evidence, but it is encouraging because treating Charcot’s foot often means managing two problems at once: broken bones and open wounds, each of which complicates healing of the other.
There is also growing interest in targeting the molecular pathways of bone destruction more precisely. Since the RANKL-RANK-OPG pathway plays a central role in the bone loss seen during acute Charcot’s foot, medications that block RANKL, such as denosumab (already approved for osteoporosis), are being investigated as potential treatments.22PubMed Central. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications Clinical trial data for these drugs in Charcot’s foot specifically are still limited, but the biological rationale is strong. If osteoclast overactivity is the engine of destruction, turning off that engine pharmacologically could potentially shorten the acute phase and reduce the severity of deformity.
Better diagnostic tools are also on the horizon. Skin temperature monitoring, already useful in the clinic, is being refined with standardized protocols. Research suggests that measuring the temperature difference between the two feet at specific time points after removing shoes, rather than a single quick measurement, gives more reliable results for both diagnosis and treatment monitoring.23PubMed Central. Infrared Dermal Thermometry in Active Charcot Neuro-Osteoarthropathy of Foot Home-use infrared thermometers could eventually allow patients to monitor their own feet daily and catch a flare before it progresses, though this approach depends on patient education and adherence, which are always the harder part of any prevention strategy.